Vaxil Provides Update on USAMRIID, Oral Experiment and Other General Business Matters

    NEXT STORY
    Auron Therapeutics Closes $12.75 Million Seed Financing to Develop Differentiation Therapies for Treatment of Cancers
    PREV STORY
    Nextech CEO Evan Gappelberg Buys 250,000 Shares of Company Stock
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    2017 Is the Year of Making Canadian Companies and Their People Healthier

    TORONTO, ON--(Marketwired - April 24, 2017) - Canada's innovative corporate wellness provider, Heidary Health, ...

    author_avatar
    NASDAQ Market News

    INNATE PHARMA : Données de Phase I avec monalizumab et durvalumab dans le MSS-CRC présentées au congrès ASCO

    Données cliniques d'un essai de Phase I évaluant monalizumab et Imfinzi® (durvalumab) chez des ...

    author_avatar
    NASDAQ Market News

    ProLynx annonce l’essai clinique de phase 1B de son agent endommageant l’ADN, PLX038 (PEG~SN-38), associé à l’inhibiteur de la PARP Rubraca® (rucaparib) au National Cancer Institute  

    author_avatar
    NASDAQ Market News